LivaNova price target raised to $61 from $57 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on LivaNova to $61 from $57 and keeps an Equal Weight rating on the shares. The analyst updated sales estimates to reflect the wind-down of the ACS business, offset by upside in Neuromod.